Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**25-Hydroxycholesterol** is an oxysterol and a hydroxylated derivative of cholesterol. It is produced endogenously in humans by the enzyme cholesterol 25-hydroxylase (CH25H), often as part of the innate immune response. Mechanistically, it acts as a regulator of intracellular cholesterol metabolism by suppressing sterol regulatory element binding proteins (SREBPs), thereby inhibiting cholesterol synthesis and uptake[8][4][6]. It also modulates autophagy and inflammation through various signaling pathways. Notably, it has broad antiviral activity against several viruses by restricting viral entry and replication via modulation of cellular lipid metabolism[4][6]. Additionally, it can induce apoptosis in certain cell types and influence immune cell migration. While not approved as a pharmaceutical drug or dietary supplement, it is widely used experimentally to study lipid metabolism, immunology, virology, and related fields[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 25-hydroxycholesterol.